Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Observational × Prostatic Neoplasms × Genes × Clear all

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 1

Interventions

Surveys and Questionnaires 30 Blood Specimen Collection 21 enzalutamide 17 Docetaxel 14 Leuprolide 13 Interviews as Topic 13 Biopsy 13 Abiraterone Acetate 13 apalutamide 12 Radiotherapy 12 Watchful Waiting 10 Observation 10 Magnetic Resonance Spectroscopy 10 Androgen Antagonists 9 radium Ra 223 dichloride 8 darolutamide 8 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 7 Radiosurgery 7 Magnetic Resonance Imaging 7 abiraterone 6 Specimen Handling 6 Brachytherapy 6 Standard of Care 5 Positron Emission Tomography Computed Tomography 5 Focus Groups 5 Amplified Fragment Length Polymorphism Analysis 5 Registries 4 Radiotherapy, Intensity-Modulated 4 Hematologic Tests 4 Gonadotropin-Releasing Hormone 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03152448 2022-06-13

P-PROVE

Myriad Genetic Laboratories, Inc.

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡